A Phase 2 interventional study of M281 in Generalized Myasthenia Gravis, sponsored by Momenta Pharmaceuticals, Inc.. Terminated at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-27.
Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 64th largest by enrollment of the 108 interventional ones that give a count, is one of 14 that started in 2019, is one of 26 in phase 2, and was the 42nd registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 14 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
This study is registered under Momenta Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Momenta Pharmaceuticals, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Johnson & Johnson has 5 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)
Participants must be ≥18 years of age with a documented history of Generalized Myasthenia Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, previously participated in the MOM-281-004 study, had no major eligibility deviations or other major protocol deviations or not met any of the stopping criteria or discontinued study drug in the MOM-M281-004 study for any reason other than the need for rescue therapy as specified in the MOM-M281-004 study.
Additional, more specific criteria are defined in the protocol.
Drug: M281
M281 injection administered as intravenous infusion
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs were reported. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug in this study.
Time frame: Up to 257 days post-baseline (Baseline is Day 1)
Number of Participants With Serious Adverse Events (SAEs)
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.
Time frame: Up to 257 days post-baseline
Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
Number of participants with treatment-emergent AESIs were reported. Severe infections and hypoalbuminemia (Grade 3 or higher according to the Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) were considered as AESIs.
Time frame: Up to 257 days post-baseline
Number of Participants With Treatment-emergent Abnormal Vital Signs
Number of participants with treatment-emergent abnormal vital signs including pulse rate (less than or equal to \[\<=\] 50 beats per minutes \[bpm\] with greater than or equal to \[\>=\] 15 bpm decrease from baseline, \>= 120 bpm with \>=15 bpm increase from baseline), systolic blood pressure (SBP) (\<= 90 millimeters of mercury \[mmHg\] with \>= 20 mmHg decrease from baseline, \>= 160 mmHg with \>= 20 mmHg increase from baseline) and diastolic blood pressure (DBP) (\<= 50 mmHg with \>=15 mmHg decrease from baseline, \>=100 mmHg with \>=15 mmHg decrease from baseline) were reported.
Time frame: Up to 257 days post-baseline
Number of Participants With Abnormalities in Physical Examinations
Number of participants with abnormalities in physical examinations (abdomen, head, ears, eyes, nose, throat, and sinuses, lungs, neurological, skin, blood and lymphatic system, cardiovascular, chest, gastrointestinal, general appearance and musculoskeletal) were reported.
Time frame: Week 12
Change From Baseline in Chemistry Laboratory Parameters: Albumin and Protein
Change from baseline in chemistry laboratory parameters: albumin and protein were reported.
Time frame: Baseline up to Week 12
Change From Baseline in Chemistry Laboratory Parameters: Bicarbonate, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium, Sodium, Triglycerides, Urate and Urea Nitrogen
Change from baseline in chemistry laboratory parameters: bicarbonate, calcium, chloride, cholesterol, glucose, phosphate, potassium, sodium, triglycerides, urate and urea nitrogen were reported.
Time frame: Baseline up to Week 12
Change From Baseline in Chemistry Laboratory Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase
Change from baseline in chemistry laboratory parameters alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), creatine kinase, gamma glutamyl transferase, lactate dehydrogenase were reported.
Time frame: Baseline up to Week 12
Change From Baseline in Chemistry Laboratory Parameters: Bilirubin, Creatinine and Direct Bilirubin
Change from baseline in chemistry laboratory parameters: bilirubin, creatinine and direct bilirubin were reported.
Time frame: Baseline up to Week 12
Change From Baseline in Hematology Laboratory Parameter: Erythrocytes (Red Blood Cell)
Change from baseline in erythrocytes (red blood cells) (hematology laboratory parameter) was reported.
Time frame: Baseline up to Week 12
Change From Baseline in Hematology Laboratory Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
Change from baseline in hematology laboratory parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes were reported.
Time frame: Baseline up to Week 12
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
Change from baseline in erythrocytes mean corpuscular hemoglobin (HGB) concentration (hematology laboratory parameter) were reported.
Time frame: Baseline up to Week 12
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB)
Change from baseline in erythrocytes mean corpuscular HGB (hematology laboratory parameter) was reported.
Time frame: Baseline up to Week 12
Change From Baseline in Hematology Laboratory Parameter: Erythrocytes Mean Corpuscular Volume
Change from baseline in erythrocytes mean corpuscular volume (hematology laboratory parameter) was reported.
Time frame: Baseline up to Week 12
Change From Baseline in Hematology Laboratory Parameter: Hematocrit
Change from baseline in hematocrit (hematology laboratory parameter) was reported.
Time frame: Baseline up to Week 12
Change From Baseline in Hematology Laboratory Parameter: Hemoglobin
Change from baseline in hemoglobin (hematology laboratory parameter) was reported.
Time frame: Baseline up to Week 12
Change From Baseline in Urinalysis Laboratory Parameter: pH
Change from baseline in pH (urinalysis laboratory parameter) was reported.
Time frame: Baseline up to Week 12
Change From Baseline in Urinalysis Laboratory Parameter: Specific Gravity
Change from baseline in specific gravity (urinalysis laboratory parameter) was reported.
Time frame: Baseline up to Week 12
Number of Participants With Treatment-emergent Abnormal Electrocardiograms (ECG) Values
Number of participants with treatment-emergent abnormal ECG values for variables including mean heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\], abnormally high refers greater than or equal to \[\>=\] 120 bpm), PR interval (abnormally low refers to \< 120 and abnormally high refers to \>200 milliseconds \[msec\]), RR interval (abnormally low refers to \<600 msec and abnormally high refers to \>1200 msec) and QRS duration (abnormally \> 120) were reported.
Time frame: Up to 257 days post-baseline
Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Scores
Number of participants with C-SSRS scores were reported. C-SSRS is a clinician-administered questionnaire designed to solicit occurrence, severity, and frequency of suicide-related ideation and behaviors. Total score ranges from 1 to 10, score of 0 was assigned (0="no event that can be assessed based on C-SSRS"). Higher total scores indicate greater severity. Maximum score assigned for each participant was summarized into one of 3 categories: no suicidal ideation or behavior (0), suicidal ideation (1 to 5): higher score indicates more suicidal ideation, suicidal behavior (6 to 10): higher score indicates more suicidal behavior. Suicidal ideation includes participants who did not have suicidal ideation or behavior at baseline and had suicidal ideation without behavior at some time point post-baseline. Suicidal behavior includes participants who did not have suicidal ideation or behavior at baseline and had suicidal behavior at some time point post-baseline (baseline=Day 1).
Time frame: Up to 257 days post-baseline
Number of Participants With Below/Above Normal Values of Coagulation Laboratory Parameter
Number of participants with at least one value above upper limit of normal (\>ULN) or below the lower limit of normal (\< LLN) value of coagulation parameters (activated partial thromboplastin time \[APTT\] and prothrombin time \[PT\]) were reported. The lab reference range for APTT is 25.1 to 36.5 seconds. The lab reference range for PT is 9.4 to 12.5 seconds.
Time frame: Up to 257 days post-baseline
Change From Baseline in Total Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score Over Time
The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
Time frame: Baseline up to Weeks 4, 8, 12, 24, End of treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score Over Time
Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or greater than or equal to (\>=) 8-point improvement in total MG-ADL score over time were reported. MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
Time frame: Weeks 4, 8, 12, 24, End of treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score Over Time
The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
Time frame: Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 Scale (MG-QoL15r) Score Over Time
The MG-QoL15r was used to assess the participant's limitations related to living with MG. It consists of 15 questions and each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.
Time frame: Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Rating Score Over Time
The CGI-S scale is the clinician/physician's global assessment of participants illness severity of MG and is rated by answering on 8-point scale. Considering total clinical experience, participant is assessed on severity of illness according to: 0=not performed; 1=normal, not at all ill; 2=borderline illness; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Higher scores indicated more severity of illness. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time.
Time frame: Baseline up to Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Number of Participants With Improvement of Illness Over Time Based on Clinical Global Impression of Improvement (CGI-I) Scale Score
Number of participants with improvement of illness based on CGI-I scale score over time were reported. The CGI-I scale is the clinician/physician's global assessment of the change in severity of the patient's generalized myasthenia gravis (gMG) since starting this study. The rating is given on a 7-point scale with lower scores indicating greater improvement (1= Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 =Minimally worse; 6 = Much worse; 7 = Very much worse. Values of 0 (not assessed) were excluded from analysis. Higher score indicates more severity.
Time frame: Weeks 4, 8, 12, 24, End of Treatment (EoT) (up to 253 days post-baseline), Follow-up (up to 257 days post-baseline)
Number of Participants With Change From Baseline in Myasthenia Gravis Foundation of America (MGFA) Classification Score Over Time
Number of participants with change from baseline in MGFA classification score over time were reported. The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).
Time frame: Weeks 8, 24 and End of Treatment (EoT) (up to 253 days post-baseline)
Number of Participants With Anti-drug Antibodies (ADA) to Nipocalimab
Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method.
Time frame: Up to 257 days post-baseline
Number of Participants With Neutralizing Antibodies (NAbs) to Nipocalimab
Number of participants with NAbs were reported. Neutralizing antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay.
Time frame: Up to 257 days post-baseline
Change From Baseline in Serum Immunoglobulin (Ig)G Concentration Over Time
Change from baseline in serum immunoglobulin (Ig)G concentration over time was reported.
Time frame: Baseline to Weeks 2, 4, 8, 12, 24, up to 253 days post-baseline, up to 257 days post-baseline
| Milestone | Placebo-Nipocalimab | Nipocalimab-Nipocalimab |
|---|---|---|
| Started | 7 | 30 |
| Completed | 0 | 0 |
| Not completed | 7 | 30 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Covid-19 | 7 | 29 |
Number of participants with TEAEs were reported. An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug in this study.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 4 | 18 | 22 |
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 1 | 4 | 5 |
Number of participants with treatment-emergent AESIs were reported. Severe infections and hypoalbuminemia (Grade 3 or higher according to the Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) were considered as AESIs.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs) | 1 | 1 | 2 |
Number of participants with treatment-emergent abnormal vital signs including pulse rate (less than or equal to \[\<=\] 50 beats per minutes \[bpm\] with greater than or equal to \[\>=\] 15 bpm decrease from baseline, \>= 120 bpm with \>=15 bpm increase from baseline), systolic blood pressure (SBP) (\<= 90 millimeters of mercury \[mmHg\] with \>= 20 mmHg decrease from baseline, \>= 160 mmHg with \>= 20 mmHg increase from baseline) and diastolic blood pressure (DBP) (\<= 50 mmHg with \>=15 mmHg decrease from baseline, \>=100 mmHg with \>=15 mmHg decrease from baseline) were reported.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Pulse rate: <=50 bpm with >=15 bpm decrease from baseline | 0 | 0 | 0 |
| Pulse rate: >= 120 bpm with >=15 bpm increase from baseline | 0 | 0 | 0 |
| SBP: <= 90 mmHg with >= 20 mmHg decrease from baseline | 0 | 1 | 1 |
| SBP: >= 160 mmHg with >= 20 mmHg increase from baseline | 0 | 1 | 1 |
| DBP: <= 50 mmHg with >=15 mmHg decrease from baseline | 0 | 2 | 2 |
| DBP: >=100 mmHg with >=15 mmHg decrease from baseline | 0 | 0 | 0 |
Number of participants with abnormalities in physical examinations (abdomen, head, ears, eyes, nose, throat, and sinuses, lungs, neurological, skin, blood and lymphatic system, cardiovascular, chest, gastrointestinal, general appearance and musculoskeletal) were reported.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Abdomen | 1 | 0 | 1 |
| Head, Ears, Eyes, Nose, Throat and Sinuses | 0 | 0 | 0 |
| Lungs | 0 | 0 | 0 |
| Neurological | 0 | 1 | 1 |
| Skin | 1 | 4 | 5 |
Change from baseline in chemistry laboratory parameters: albumin and protein were reported.
| grams per liter (g/L) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Albumin | -1.5 ± 2.89 | -1.2 ± 3.21 | -1.3 ± 3.08 |
| Protein | -3.5 ± 2.08 | -3.8 ± 4.99 | -3.7 ± 4.54 |
Change from baseline in chemistry laboratory parameters: bicarbonate, calcium, chloride, cholesterol, glucose, phosphate, potassium, sodium, triglycerides, urate and urea nitrogen were reported.
| millimoles per liter (mmol/L) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Bicarbonate | -2.0 ± 2.45 | 1.6 ± 2.91 | 1.0 ± 3.14 |
| Calcium | 0.010 ± 0.0627 | -0.018 ± 0.1005 | -0.013 ± 0.0938 |
| Chloride | 0.5 ± 1.91 | 0.6 ± 2.85 | 0.6 ± 2.66 |
| Cholesterol | 0.480 ± 1.0100 | 0.261 ± 0.5732 | 0.303 ± 0.6509 |
| Glucose | 0.280 ± 0.5054 | -0.258 ± 1.1401 | -0.155 ± 1.0607 |
| Phosphate | -0.018 ± 0.0971 | -0.002 ± 0.1903 | -0.005 ± 0.1744 |
| Potassium | 0.05 ± 0.173 | 0.05 ± 0.583 | 0.05 ± 0.526 |
| Sodium | 0.8 ± 0.96 | 1.4 ± 2.18 | 1.2 ± 2.00 |
| Triglycerides | 0.223 ± 0.5799 | 0.081 ± 0.3223 | 0.108 ± 0.3699 |
| Urate | -0.0090 ± 0.04285 | 0.0174 ± 0.04790 | 0.124 ± 0.04716 |
| Urea Nitrogen | -0.270 ± 1.7830 | -0.105 ± 1.7292 | -0.136 ± 1.6951 |
Change from baseline in chemistry laboratory parameters alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), creatine kinase, gamma glutamyl transferase, lactate dehydrogenase were reported.
| units per liter (U/L) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| ALT | 17.0 ± 28.76 | 2.6 ± 5.33 | 5.3 ± 13.43 |
| Alkaline Phosphatase | 6.3 ± 2.06 | 5.2 ± 11.46 | 5.4 ± 10.23 |
| AST | 23.5 ± 47.67 | 0.9 ± 3.42 | 5.2 ± 20.80 |
| Creatine Kinase | -17.8 ± 33.13 | 13.6 ± 38.34 | 7.7 ± 38.73 |
| Gamma Glutamyl Transferase | 4.3 ± 11.95 | 1.5 ± 13.21 | 2.0 ± 12.74 |
| Lactate Dehydrogenase | 30.0 ± 15.68 | 30.9 ± 58.10 | 30.7 ± 52.00 |
Change from baseline in chemistry laboratory parameters: bilirubin, creatinine and direct bilirubin were reported.
| micromoles per liter (micromol/L) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Bilirubin | 0.13 ± 2.616 | -0.59 ± 2.403 | -0.46 ± 2.393 |
| Creatinine | -9.0 ± 7.35 | -2.6 ± 13.20 | -3.9 ± 12.41 |
| Direct Bilirubin | -1.20 ± NA | -0.70 ± 0.283 | -0.87 ± 0.359 |
Change from baseline in erythrocytes (red blood cells) (hematology laboratory parameter) was reported.
| 10^12 cells count per Liter | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Change From Baseline in Hematology Laboratory Parameter: Erythrocytes (Red Blood Cell) | 0.188 ± 0.0822 | 0.121 ± 0.2702 | 0.135 ± 0.2438 |
Change from baseline in hematology laboratory parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes were reported.
| 10^9 cells count per Liter | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Basophils | -0.003 ± 0.0150 | 0.010 ± 0.0200 | 0.006 ± 0.0188 |
| Eosinophils | 0.015 ± 0.0465 | 0.013 ± 0.0776 | 0.014 ± 0.0702 |
| Lymphocytes | -0.045 ± 0.4498 | 0.063 ± 0.4715 | 0.041 ± 0.4576 |
| Monocytes | -0.105 ± 0.1964 | 0.059 ± 0.2008 | 0.027 ± 0.2061 |
| Neutrophils | -0.433 ± 0.5744 | 0.411 ± 1.8622 | 0.243 ± 1.7058 |
| Platelets | 27.8 ± 11.81 | 12.3 ± 53.20 | 15.4 ± 47.93 |
| Leukocytes | -0.568 ± 0.9214 | 0.567 ± 1.9956 | 0.340 ± 1.8694 |
Change from baseline in erythrocytes mean corpuscular hemoglobin (HGB) concentration (hematology laboratory parameter) were reported.
| grams per Liter (g/L) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration | -6.5 ± 25.70 | -2.1 ± 7.61 | -3.0 ± 12.38 |
Change from baseline in erythrocytes mean corpuscular HGB (hematology laboratory parameter) was reported.
| picograms (pg) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (HGB) | 0.03 ± 0.873 | -0.61 ± 0.813 | -0.48 ± 0.842 |
Change from baseline in erythrocytes mean corpuscular volume (hematology laboratory parameter) was reported.
| femtoliters (fL) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Change From Baseline in Hematology Laboratory Parameter: Erythrocytes Mean Corpuscular Volume | 2.45 ± 6.174 | -1.41 ± 3.406 | -0.64 ± 4.206 |
Change from baseline in hematocrit (hematology laboratory parameter) was reported.
| liter of cells per liter of blood (L/L) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Change From Baseline in Hematology Laboratory Parameter: Hematocrit | 0.0278 ± 0.03542 | 0.0048 ± 0.02401 | 0.0094 ± 0.02725 |
Change from baseline in hemoglobin (hematology laboratory parameter) was reported.
| g/L | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Change From Baseline in Hematology Laboratory Parameter: Hemoglobin | 5.8 ± 4.65 | 0.6 ± 7.29 | 1.7 ± 7.06 |
Change from baseline in pH (urinalysis laboratory parameter) was reported.
| pH | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Change From Baseline in Urinalysis Laboratory Parameter: pH | -0.8 ± 0.96 | 0.0 ± 1.06 | -0.1 ± 1.06 |
Change from baseline in specific gravity (urinalysis laboratory parameter) was reported.
| ratio | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Change From Baseline in Urinalysis Laboratory Parameter: Specific Gravity | -0.0003 ± 0.00660 | -0.0030 ± 0.00973 | -0.0025 ± 0.00914 |
Number of participants with treatment-emergent abnormal ECG values for variables including mean heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\], abnormally high refers greater than or equal to \[\>=\] 120 bpm), PR interval (abnormally low refers to \< 120 and abnormally high refers to \>200 milliseconds \[msec\]), RR interval (abnormally low refers to \<600 msec and abnormally high refers to \>1200 msec) and QRS duration (abnormally \> 120) were reported.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| ECG Mean Heart Rate (<= 50) | 0 | 5 | 5 |
| ECG Mean Heart Rate (>=120) | 0 | 0 | 0 |
| PR Interval (<120) | 0 | 0 | 0 |
| PR Interval (> 200) | 0 | 5 | 5 |
| RR Interval (<600) | 0 | 0 | 0 |
| RR Interval (>=1200) | 0 | 4 | 4 |
| QRS Duration (>120) | 1 | 3 | 4 |
Number of participants with C-SSRS scores were reported. C-SSRS is a clinician-administered questionnaire designed to solicit occurrence, severity, and frequency of suicide-related ideation and behaviors. Total score ranges from 1 to 10, score of 0 was assigned (0="no event that can be assessed based on C-SSRS"). Higher total scores indicate greater severity. Maximum score assigned for each participant was summarized into one of 3 categories: no suicidal ideation or behavior (0), suicidal ideation (1 to 5): higher score indicates more suicidal ideation, suicidal behavior (6 to 10): higher score indicates more suicidal behavior. Suicidal ideation includes participants who did not have suicidal ideation or behavior at baseline and had suicidal ideation without behavior at some time point post-baseline. Suicidal behavior includes participants who did not have suicidal ideation or behavior at baseline and had suicidal behavior at some time point post-baseline (baseline=Day 1).
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| No Suicidal Ideation/Behavior | 5 | 30 | 35 |
| Suicidal Ideation | 1 | 0 | 1 |
| Suicidal Behavior | 0 | 0 | 0 |
The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
| score on a scale | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Week 4 | 0.6 ± 1.34 | -0.6 ± 2.42 | -0.4 ± 2.30 |
| Week 8 | -0.8 ± 3.70 | -0.9 ± 2.63 | -0.9 ± 2.80 |
| Week 12 | -0.3 ± 4.35 | -1.2 ± 2.49 | -1.0 ± 2.82 |
| Week 24 | -1.0 ± NA | -1.2 ± 1.92 | -1.2 ± 1.72 |
| EoT (up to 253 days post-baseline) | — | -2.4 ± 2.55 | -2.4 ± 2.55 |
| Follow-up (up to 257 days post-baseline) | -0.6 ± 1.14 | 1.2 ± 3.08 | 0.9 ± 2.91 |
Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or greater than or equal to (\>=) 8-point improvement in total MG-ADL score over time were reported. MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Week 4 (2 Point Improvement) | — | 2 | 2 |
| Week 4 (3 Point Improvement) | — | 1 | 1 |
| Week 4 (4 Point Improvement) | — | 0 | 0 |
| Week 4 (5 Point Improvement) | — | 1 | 1 |
| Week 4 (6 Point Improvement) | — | 2 | 2 |
| Week 4 (7 Point Improvement) | — | 0 | 0 |
| Week 4 (>= 8 Point Improvement) | — | 0 | 0 |
| Week 8 (2 Point Improvement) | 1 | 2 | 3 |
| Week 8 (3 Point Improvement) | 0 | 4 | 4 |
| Week 8 (4 Point Improvement) | 0 | 0 | 0 |
| Week 8 (5 Point Improvement) | 0 | 0 | 0 |
| Week 8 (6 Point Improvement) | 1 | 0 | 1 |
| Week 8 (7 Point Improvement) | 0 | 0 | 0 |
| Week 8 (>= 8 Point Improvement) | 0 | 1 | 1 |
| Week 12 (2 Point Improvement) | 0 | 2 | 2 |
| Week 12 (3 Point Improvement) | 0 | 0 | 0 |
| Week 12 (4 Point Improvement) | 0 | 0 | 0 |
| Week 12 (5 Point Improvement) | 0 | 0 | 0 |
| Week 12 (6 Point Improvement) | 1 | 3 | 4 |
| Week 12 (7 Point Improvement) | 0 | 0 | 0 |
| Week 12 (>= 8 Point Improvement) | 0 | 0 | 0 |
| Week 24 (2 Point Improvement) | — | 1 | 1 |
| Week 24 (3 Point Improvement) | — | 0 | 0 |
| Week 24 (4 Point Improvement) | — | 1 | 1 |
| Week 24 (5 Point Improvement) | — | 0 | 0 |
| Week 24 (6 Point Improvement) | — | 0 | 0 |
| Week 24 (7 Point Improvement) | — | 0 | 0 |
| Week 24 (>= 8 Point Improvement) | — | 0 | 0 |
| EoT (up to 253 days post-baseline) (2 Point Improvement) | — | 2 | 2 |
| EoT (up to 253 days post-baseline) (3 Point Improvement) | — | 2 | 2 |
| EoT (up to 253 days post-baseline) (4 Point Improvement) | — | 0 | 0 |
| EoT (up to 253 days post-baseline) (5 Point Improvement) | — | 1 | 1 |
| EoT (up to 253 days post-baseline) (6 Point Improvement) | — | 1 | 1 |
| EoT (up to 253 days post-baseline) (7 Point Improvement) | — | 2 | 2 |
| EoT (up to 253 days post-baseline) (>= 8 Point Improvement) | — | 0 | 0 |
| Follow-up (up to 257 days post-baseline) (2 Point Improvement) | 1 | 3 | 4 |
| Follow-up (up to 257 days post-baseline) (3 Point Improvement) | 0 | 1 | 1 |
| Follow-up (up to 257 days post-baseline) (4 Point Improvement) | 0 | 0 | 0 |
| Follow-up (up to 257 days post-baseline) (5 Point Improvement) | 0 | 0 | 0 |
| Follow-up (up to 257 days post-baseline) (6 Point Improvement) | 0 | 0 | 0 |
| Follow-up (up to 257 days post-baseline) (7 Point Improvement) | 0 | 0 | 0 |
| Follow-up (up to 257 days post-baseline) (>= 8 Point Improvement) | 0 | 0 | 0 |
The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
| score on a scale | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Week 4 | 1.5 ± 6.36 | -1.3 ± 2.60 | -0.8 ± 3.28 |
| Week 8 | -3.0 ± 5.66 | 1.0 ± 1.53 | 0.1 ± 2.98 |
| Week 12 | -0.5 ± 3.54 | -1.2 ± 2.23 | -1.0 ± 2.33 |
| Week 24 | — | -2.7 ± 1.53 | -2.7 ± 1.53 |
| EoT (up to 253 days post-baseline) | — | -2.4 ± 4.12 | -2.4 ± 4.12 |
| Follow-up (up to 257 days post-baseline) | -3.0 ± NA | -1.6 ± 2.07 | -1.8 ± 1.98 |
The MG-QoL15r was used to assess the participant's limitations related to living with MG. It consists of 15 questions and each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.
| score on a scale | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Week 4 | 1.4 ± 3.85 | -2.2 ± 4.53 | -1.6 ± 4.57 |
| Week 8 | -0.4 ± 3.97 | -1.9 ± 4.34 | -1.6 ± 4.23 |
| Week 12 | -1.0 ± 6.27 | -3.4 ± 4.70 | -2.9 ± 4.95 |
| Week 24 | -3.0 ± NA | -1.4 ± 1.52 | -1.7 ± 1.51 |
| EoT (up to 253 days post-baseline) | — | -3.7 ± 5.28 | -3.7 ± 5.28 |
| Follow-up (up to 257 days post-baseline) | -1.3 ± 5.72 | 0.1 ± 3.11 | -0.2 ± 3.69 |
The CGI-S scale is the clinician/physician's global assessment of participants illness severity of MG and is rated by answering on 8-point scale. Considering total clinical experience, participant is assessed on severity of illness according to: 0=not performed; 1=normal, not at all ill; 2=borderline illness; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Higher scores indicated more severity of illness. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time.
| score on a scale | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Week 4 | -0.2 ± 0.84 | -0.3 ± 0.60 | -0.3 ± 0.63 |
| Week 8 | -1.0 ± 0.71 | -0.6 ± 0.90 | -0.7 ± 0.86 |
| Week 12 | -0.5 ± 1.00 | -0.5 ± 0.80 | -0.5 ± 0.81 |
| Week 24 | 0.0 ± NA | -0.6 ± 0.89 | -0.5 ± 0.84 |
| EoT (up to 253 days post-baseline) | — | -0.7 ± 0.95 | -0.7 ± 0.95 |
| Follow-up (up to 257 days post-baseline) | -1.0 ± 1.22 | -0.1 ± 0.73 | -0.3 ± 0.88 |
Number of participants with improvement of illness based on CGI-I scale score over time were reported. The CGI-I scale is the clinician/physician's global assessment of the change in severity of the patient's generalized myasthenia gravis (gMG) since starting this study. The rating is given on a 7-point scale with lower scores indicating greater improvement (1= Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 =Minimally worse; 6 = Much worse; 7 = Very much worse. Values of 0 (not assessed) were excluded from analysis. Higher score indicates more severity.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Week 4 (Very much worse) | 0 | 0 | 0 |
| Week 4 (Much worse) | 0 | 0 | 0 |
| Week 4 (Minimally worse) | 1 | 2 | 3 |
| Week 4 (No change) | 1 | 7 | 8 |
| Week 4 (Minimally improved) | 2 | 12 | 14 |
| Week 4 (Much improved) | 0 | 5 | 5 |
| Week 4 (Very much improved) | 1 | 0 | 1 |
| Week 8 (Very much worse) | 0 | 0 | 0 |
| Week 8 (Much worse) | 0 | 0 | 0 |
| Week 8 (Minimally worse) | 0 | 2 | 2 |
| Week 8 (No change) | 0 | 3 | 3 |
| Week 8 (Minimally improved) | 2 | 6 | 8 |
| Week 8 (Much improved) | 2 | 8 | 10 |
| Week 8 (Very much improved) | 1 | 0 | 1 |
| Week 12 (Very much worse) | 0 | 0 | 0 |
| Week 12 (Much worse) | 0 | 0 | 0 |
| Week 12 (Minimally worse) | 0 | 2 | 2 |
| Week 12 (No change) | 2 | 1 | 3 |
| Week 12 (Minimally improved) | 1 | 3 | 4 |
| Week 12 (Much improved) | 1 | 10 | 11 |
| Week 12 (Very much improved) | 0 | 1 | 1 |
| Week 24 (Very Much worse) | 0 | 0 | 0 |
| Week 24 (Much worse) | 0 | 0 | 0 |
| Week 24 (Minimally worse) | 0 | 0 | 0 |
| Week 24 (No change) | 1 | 0 | 1 |
| Week 24 (Minimally improved) | 0 | 1 | 1 |
| Week 24 (Much improved) | 0 | 4 | 4 |
| Week 24 (Very Much improved) | 0 | 0 | 0 |
| EoT (up to 253 days post-baseline)(Very Much worse) | — | 0 | 0 |
| EoT (up to 253 days post-baseline)(Much worse) | — | 0 | 0 |
| EoT (up to 253 days post-baseline) (Minimally worse) | — | 0 | 0 |
| EoT (up to 253 days post-baseline) (No change) | — | 1 | 1 |
| EoT (up to 253 days post-baseline)(Minimally improved) | — | 7 | 7 |
| EoT (up to 253 days post-baseline)(Much improved) | — | 7 | 7 |
| EoT (up to 253 days post-baseline)(Very much improved) | — | 1 | 1 |
| Follow-up (up to 257 days post-baseline) (Very Much worse) | 0 | 0 | 0 |
| Follow-up (up to 257 days post-baseline) (Much worse) | 1 | 2 | 3 |
| Follow-up (up to 257 days post-baseline) (Minimally worse) | 0 | 3 | 3 |
| Follow-up (up to 257 days post-baseline) (No change) | 0 | 5 | 5 |
| Follow-up (up to 257 days post-baseline) (Minimally improved) | 0 | 8 | 8 |
| Follow-up (up to 257 days post-baseline) (Much improved) | 3 | 2 | 5 |
| Follow-up (up to 257 days post-baseline) (Very much improved) | 1 | 1 | 2 |
Number of participants with change from baseline in MGFA classification score over time were reported. The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Week 8 (Improved) | 1 | 5 | 6 |
| Week 8 (Same) | 3 | 3 | 6 |
| Week 8 (Worsened) | 0 | 1 | 1 |
| Week 24 (Improved) | 0 | 0 | 0 |
| Week 24 (Same) | 1 | 1 | 2 |
| Week 24 (Worsened) | 0 | 0 | 0 |
| EoT (up to 253 days post-baseline)(Improved) | — | 4 | 4 |
| EoT (up to 253 days post-baseline)(Same) | — | 3 | 3 |
| EoT (up to 253 days post-baseline)(Worsened) | — | 1 | 1 |
Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADA) to Nipocalimab | 1 | 16 | 17 |
Number of participants with NAbs were reported. Neutralizing antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Number of Participants With Neutralizing Antibodies (NAbs) to Nipocalimab | 0 | 4 | 4 |
Number of participants with at least one value above upper limit of normal (\>ULN) or below the lower limit of normal (\< LLN) value of coagulation parameters (activated partial thromboplastin time \[APTT\] and prothrombin time \[PT\]) were reported. The lab reference range for APTT is 25.1 to 36.5 seconds. The lab reference range for PT is 9.4 to 12.5 seconds.
| Participants | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| APTT (>ULN) | 2 | 15 | 17 |
| APTT (<LLN) | 0 | 3 | 3 |
| PT (>ULN) | 1 | 8 | 9 |
| PT (<ULN) | 0 | 1 | 1 |
Change from baseline in serum immunoglobulin (Ig)G concentration over time was reported.
| g/L | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Nipocalimab (All Participants) |
|---|---|---|---|
| Week 2 | -6.888 ± 0.6104 | -5.457 ± 1.2510 | -5.681 ± 1.2804 |
| Week 4 | -3.234 ± 1.1858 | -2.796 ± 0.9728 | -2.866 ± 1.0014 |
| Week 8 | -2.996 ± 1.3773 | -3.122 ± 1.3466 | -3.095 ± 1.3235 |
| Week 12 | -3.243 ± 1.6378 | -3.639 ± 2.2627 | -3.563 ± 2.1269 |
| Week 24 | -3.870 ± NA | -4.072 ± 1.2826 | -4.038 ± 1.1502 |
| 253 days post-baseline | — | -3.494 ± 1.9208 | -3.494 ± 1.9208 |
| 257 days post-baseline | -1.150 ± 0.5687 | -0.020 ± 1.6162 | -0.289 ± 1.5056 |
Collected over Up to 257 days post-baseline (Day 1). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Nipocalimab | 0/7 (0%) | 1/7 (14.3%) | 4/7 (57.1%) |
| Nipocalimab-Nipocalimab | 1/30 (3.3%) | 4/30 (13.3%) | 17/30 (56.7%) |
| Event | Placebo-Nipocalimab | Nipocalimab-Nipocalimab |
|---|---|---|
| Covid-19 PneumoniaInfections and infestations | 1/7 | 0/30 |
| Myasthenia GravisNervous system disorders | 0/7 | 2/30 |
| Coronavirus InfectionInfections and infestations | 0/7 | 1/30 |
| GliosarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 1/30 |
| Event | Placebo-Nipocalimab | Nipocalimab-Nipocalimab |
|---|---|---|
| Vertigo PositionalEar and labyrinth disorders | 1/7 | 0/30 |
| ToothacheGastrointestinal disorders | 1/7 | 0/30 |
| Oedema PeripheralGeneral disorders | 1/7 | 3/30 |
| Blood Immunoglobulin G DecreasedInvestigations | 1/7 | 4/30 |
| Hepatic Enzyme IncreasedInvestigations | 1/7 | 0/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/7 | 1/30 |
| Myasthenia GravisNervous system disorders | 1/7 | 0/30 |
| Depressed MoodPsychiatric disorders | 1/7 | 0/30 |
| Rash Maculo-PapularSkin and subcutaneous tissue disorders | 1/7 | 0/30 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 2/30 |
| Age, Categorical(Participants) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 20 | 25 |
| >=65 years | 2 | 10 | 12 |
| Age, Continuous(years) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Total |
|---|---|---|---|
| Mean | 53.7 ± 20.39 | 53 ± 16.93 | 53.2 ± 17.33 |
| Sex: Female, Male(Participants) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Total |
|---|---|---|---|
| Female | 4 | 18 | 22 |
| Male | 3 | 12 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 5 | 28 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 5 | 29 | 34 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Other | 2 | 0 | 2 |
| Region of Enrollment(Participants) | Placebo-Nipocalimab | Nipocalimab-Nipocalimab | Total |
|---|---|---|---|
| GERMANY | 1 | 1 | 2 |
| ITALY | 0 | 2 | 2 |
| POLAND | 0 | 7 | 7 |
| SPAIN | 4 | 7 | 11 |
| UNITED STATES | 2 | 13 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Dec 2020, 16 months.
Results were first posted in Feb 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nipocalimab
Momenta Pharmaceuticals, Inc. →